Pancreatic β-cell dysfunction or loss is the hallmark of all forms of diabetes ([@B1],[@B2]). Transcription factors have proven to be critical for the maintenance of normal β-cell function, and mutations in many of these, including pancreatic duodenum homeobox-1 (PDX1) ([@B3]) and the hepatocyte nuclear factors HNF1α ([@B4]) and HNF4α ([@B5]) lead to monogenic forms of inherited type 2 diabetes ([@B6]), whereas polymorphisms in others, notably T-cell factor 7-like 2 (TCF7L2), are associated with more common forms of the disease ([@B7]).

Recently, a transcription factor termed aryl hydrocarbon receptor nuclear translocator (ARNT), or hypoxia-inducible factor-1β (HIF-1β), has emerged as a potentially important player in the pathogenesis of pancreatic β-cell dysfunction and type 2 diabetes in humans ([@B8]). ARNT/HIF-1β is a member of the basic helix-loop-helix (HLH) Per/AhR/ARNT/Sim (PAS) family of transcription factors and binds DNA as an obligate heterodimer with the oxygen-sensitive HIF-1α, HIF-2α, or aryl hydrocarbon receptor (AhR). When mRNA levels were compared in human pancreatic islets of Langerhans isolated from five type 2 diabetic donors and seven nondiabetic donors by oligonucleotide microarrays and real-time PCR, an 82% reduction in the expression of the ARNT/HIF-1β gene was observed in islets from type 2 diabetic donors. Confirming a role for ARNT/HIF-1β in β-cell function, β-cell--specific ARNT/HIF-1β gene knockout in mice, or ARNT/HIF-1β silencing in MIN6 cells, led to defects in glucose-stimulated insulin secretion (GSIS) and alterations in islet gene expression comparable to those observed in human type 2 islets ([@B8]).

Carbohydrate-responsive element-binding protein (ChREBP) ([@B9]) (also termed MondoB or Williams-Beuren syndrome critical region gene 14 \[WBSCR14\]) ([@B10]) is a transcription factor that regulates de novo lipogenesis in the liver in response to elevated glucose concentrations ([@B11]). It is a member of the basic HLH (bHLH) family and transactivates glucose-responsive genes by binding DNA on carbohydrate response element (ChoRE), as a heterodimer with Max-like protein X (MLX) ([@B12]). In addition to its lipogenic role in the liver, we have recently shown ([@B13]) that, in clonal pancreatic β-cells, *1*) ChREBP mRNA levels are increased in response to elevated glucose concentrations; *2*) ChREBP translocates to the nucleus in response to high glucose; *3*) ChREBP directly binds to the promoters of lipogenic genes fatty acid synthase (FAS) and [l]{.smallcaps}-type pyruvate kinase ([l]{.smallcaps}-PK) in a glucose- and calcium-dependent, but insulin-independent, manner in intact cells; and *4*) ChREBP silencing by small-interfering RNA (siRNA) improves GSIS ([@B13]).

To identify other genes directly regulated by ChREBP in the β-cell, we performed a genome-wide analysis of the ChREBP transcriptome using chromatin immunoprecipitation and high-density oligonucleotide tiling arrays (ChIP-on-chip; Agilent Technologies) in MIN6 cells. ARNT/HIF-1β fell within the statistical cutoff and was considered positive for ChREBP binding. Consequently, we demonstrate that ChREBP directly binds to ARNT/HIF-1β promoter in a glucose-dependent manner in clonal MIN6 and INS-1 (832/13) cells and negatively regulates ARNT/HIF-1β gene expression in pancreatic islet β-cells.

These results suggest that ChREBP, in addition to being a critical regulator of lipogenic genes in the liver and pancreatic β-cell, may also play a role in the development of β-cell failure and type 2 diabetes through alteration of ARNT/HIF-1β gene expression.

RESEARCH DESIGN AND METHODS
===========================

Reagents.
---------

The Silencer siRNA construction kit was from Ambion (Huntingdon, U.K.). Primers for siRNA construction and PCR were from MWG Biotech (Milton Keynes, U.K.). TransIT-TKO transfection reagent was from Mirrus (Madison, WI). The rat insulin radioimmunoassay kit was from Linco (St. Charles, MO). Tissue culture reagents were from Sigma-Aldrich (Dorset, U.K.) or Invitrogen (Paisley, U.K.). Lipofectamine 2000 and SYBR Green platinum were from Invitrogen (Paisley, U.K.). Collagenase from *C. histolyticum* was obtained from Serva Electrophoresis (Heidelberg, Germany). Anti-ChREBP antibody was described by da Silva Xavier et al. ([@B13]). Mouse monoclonal anti-hemaglutinin (HA) antibody was provided by Anindiya Roy (Cancer Research U.K.). Other reagents were from Sigma or Fisher.

Plasmids, adenoviruses, and SiRNA generation.
---------------------------------------------

Plasmid pChREBP was described ([@B13]). Plasmid bearing HA-tagged MLX cDNA was provided by Dr H. Towle (University of Minnesota). Plasmid pARNT-2369.Luc~FF~ was generated by PCR using MIN6 genomic DNA, AccuPrime *Taq*DNA Polymerase High Fidelity (Invitrogen), and the following primers: forward, 5′-cgcg *[GAGCTC]{.ul}* CAC AAG CTA AGA TCA TCT GAG AGG (*Sac*I site underlined) and reverse, 5′-cgcg *[CTCGAG]{.ul}* GTT ACT TAC TAG GCA TCA GGG GAA (*Xho*I site underlined). The resulting 2,662-bp fragment was subcloned into pCR2.1 by TA cloning, digested by *Sac*I, and subcloned into pGL3basic (Promega) at the *Sac*I site. Plasmids pARNT-1028.Luc~FF~, pARNT-630.Luc~FF~, and pARNT-1028-769.Luc~FF~ were generated by digesting pARNT-2369.Luc~FF~ with *Bgl*II, *Kpn*I, and *Spe*I, respectively, gel purification, and self-ligation. Plasmids pARNT-1028\[-443T\>A;-442\_-402del\].Luc~FF~ and pARNT-630\[-440\_-402del\].Luc~FF~ were generated by PCR using plasmids pARNT-1028.Luc~FF~ and pARNT-630.Luc~FF~ as templates, respectively; Phusion Hot Start High-Fidelity DNA Polymerase (Finnzymes); and the following primers: forward, 5′- TTCTCTTTGCATTTCACTGACG and reverse, 5′- TCATCAGCATATGCTTCCTACAGAC. The resulting PCR products were gel purified, phosphorylated using T4 kinase and forward buffer (Invitrogen), and self-ligated. The differences in the sequences of the resulting deletion mutants is probably because the primers used were not PAGE purified. The E-boxes point mutations in pARNT-1028.Luc~FF~ and pARNT-630.Luc~FF~ plasmids were introduced using a QuikChange Site-Directed Mutagenesis Kit (Stratagene). Primer sequences for each mutant are available on demand. pLPK-183.Luc~FF~ has been described previously ([@B14]). pRL-CMV was from Promega. Adenovirus-encoding ChREBP was generated by subcloning ChREBP cDNA into pAdTrackCMV using *Not*I-*Xba*I sites and then amplified according to He et al. ([@B15]) and Ainscow and Rutter ([@B16]). Adenovirus encoding GFP was described by Leclerc et al. ([@B17]). All constructs were verified by DNA sequencing. SiRNAs were generated as described by da Silva Xavier et al. ([@B13]) using The Silencer siRNA construction kit from Ambion and the following primers (T7 underlined): rat ChREBP, 508 AAACCTGAGGCTGTTGTCTT[CCTGTCTC]{.ul} 527; scrambled, AAGGCTGTTTCACCTGAGTT [CCTGTCTC]{.ul}.

Islet isolation and culture.
----------------------------

Male CD1 mice (12--13 weeks old) were killed by cervical dislocation, and collagenase (1.0 mg/ml in Hanks\' balanced salt solution) was injected into the pancreatic duct (5.0 ml/mouse). The distended pancreata were then incubated in a shaking water bath at 37°C in 1.0 mg/ml collagenase in Hanks\' balanced salt solution for 10 min, and the islets were recovered using Histopaque gradient solutions (3 ml of 1.119 g/l; 3 ml of 1.083 g/l; 3 ml of 1.077 g/l). After centrifugation for 20 min at 2,500*g*, islets were removed from the top layer and washed once with RPMI 1640. Mouse islets were maintained in RPMI 1640 medium supplemented with 10% heat-inactivated FCS plus antibiotics and incubated in a humidified atmosphere at 37°C with 5% CO~2~. Infection of islets with adenoviruses was performed at a multiplicity of infection of 100, and islets of no greater than 150 μm diameter were used to ensure infection of 30--50% of cells within each islet ([@B18]). Measurements of insulin secretion were performed 48 h after infection.

Cell culture and transfection.
------------------------------

MIN6 β-cells ([@B19]) were used between passages 19 and 30 and grown in Dulbecco\'s modified Eagle\'s medium containing 25 mmol/l glucose and supplemented with 15% (vol/vol) heat-inactivated FCS, 4 mmol/l [l]{.smallcaps}-glutamine, 25 μmol/l β-mercaptoethanol, 100 IU/ml penicillin, and 100 μg/ml streptomycin in a humidified atmosphere at 37°C with 5% CO~2~ unless specified otherwise. INS-1 (832/13) β-cells ([@B20]) were cultured in RPMI 1640 containing 11 mmol/l glucose, 10% (vol/vol) FCS, 4 mmol/l [l]{.smallcaps}-glutamine, 100 IU/ml penicillin, 100 μg/ml streptomycin, 10 mmol/l HEPES, 1 mmol/l sodium pyruvate, 0.05 mmol/l β-mercaptoethanol, or as indicated. HEK293 cells were cultured in Dulbecco\'s modified Eagle\'s medium containing 10% (vol/vol) heat-inactivated FCS, 25 mmol/l glucose, 2 mmol/l glutamine, 100 IU/ml penicillin, and 100 μg/ml streptomycin. INS1 (832/13) cells were transfected using Lipofectamine 2000 and Opti-Mem, according to the manufacturer\'s instructions, whereas HEK293 cells were transfected using the calcium phosphate method, pH 7.12 ([@B21]).

Chromatin immunoprecipitation assay and ChIP-on-chip.
-----------------------------------------------------

Chromatin immunoprecipitation was performed as described by da Silva Xavier et al. ([@B13]). Briefly, MIN6 β or INS-1(832/13) cells were cultured in medium containing 3 mmol/l glucose for 16 h before stimulation with medium containing 3 or 30 mmol/l \[20 mmol/l for INS-1(832/13)\] glucose for 20 h before cross-linking with 1% formaldehyde and sonication to obtain fragments of chromatin \<1 kb. DNA-protein complexes were immunoprecipitated with antibodies against ChREBP or HA, followed by digestion with proteinase K (Boehringer Mannheim). The resulting DNA was extracted using phenol-chloroform and precipitated with ethanol. The mouse ARNT/HIF-1β promoter from −530 to −249 bp was amplified using the following primers: 5′-TGCTGATGAGCCCACTAAGA-3′ and 5′-ATAGAGGCCGGGCTAGTGAC-3′. The mouse ARNT/HIF-1β promoter from −1,059 bp to −759 bp and −392 bp to 94 bp was amplified using the following primer pairs: 5′-GTCTTCAAACACACCAGACGA-3′ and 5′-GTGAGGTGTCCTATGTCAC-3′; 5′-CAGAAAGGACTGACAAGTGC-3′ and 5′-GCTGGCAGAGGGTTAAAAG-3′, respectively. The sequence of the mouse [l]{.smallcaps}-PK primers are given in the study by da Silva Xavier et al. ([@B13]). The rat ARNT/HIF-1β promoter from −197 to −609 bp was amplified using the following primers: 5′-TTGCCTAGGAAGCACAAGG-3′ and 5′-AGCCTCCC TGGGAAAACTGACC-3′ and the rat ARNT/HIF-1β promoter −1,001 to −1,300 bp was amplified using the following primers: 5′-GTCAGTCTAGGCTACTTGAG-3′ and 5′-GGGCTAGTGGTGCATACCTTTAATC-3′. The rat [l]{.smallcaps}-PK promoter from 129 to −392 bp was amplified using the following primers: 5′-AAAGTCTGCCTTAAGTGGGGC-3′ and 5′-TCCACCTTCCCTCCACCCA-3′. ChIP-on-chip was carried out using Agilent high-density oligonucleotide tiling arrays (Agilent Technologies, Cheshire, U.K.) according to the manufacturer\'s protocol. The antibody-enriched DNA was blunt-ended and ligated to specific linker and amplified using a two-stage PCR protocol. Fluorescence dyes Cy3 (3 mmol/l glucose) and Cy5 (30 mmol/l glucose) were used to label the antibody-enriched DNA. The DNA was hybridized onto microarray slides for up to 40 h at 40°C. The slides were washed, and the data were analyzed by high-resolution scanning and Agilent ChIP Analytics software. To detect significant binding events, a minimum cutoff *P* value of \<0.001 was used.

RNA isolation and quantitative real-time PCR.
---------------------------------------------

Primary mouse pancreatic islets were treated for 24 h with ChREBP or null adenovirus in culture medium containing 11 mmol/l glucose and then incubated for 16 h at 3 mmol/l glucose and finally for 20 h at either 3 or 17 mmol/l glucose as indicated. Levels of mRNA encoding the indicated genes were determined by quantitative real-time RT-PCR and were normalized compared with cyclophillin mRNA as described by da Silva Xavier et al. ([@B22]). Results are expressed as the fold change over control (null, 3 mmol/l glucose) and presented as the means ± SE.

Insulin secretion and assay.
----------------------------

After adenoviral infection (48 h), islets were incubated for 60 min in a shaking water bath at 37°C in 1 ml Krebs-Ringer bicarbonate HEPES buffer: 125 mmol/l NaCl, 3.5 mmol/l KCl, 1.5 mmol/l CaCl~2~, 0.5 mmol/l MgSO~4~, 0.5 mmol/l NaH~2~PO~4~, 2.0 mmol/l NaHCO~3~, 10 mmol/l HEPES) supplemented with 3 mmol/l glucose/0.1% (wt/vol) BSA, equilibrated with a mixture of 95% O~2~/5% CO~2~, pH 7.4. The islets were then separated into four groups of six islets per condition and incubated for 30 min in 1.0 ml Krebs-Ringer bicarbonate HEPES buffer as above, containing either 3 or 17 mmol/l glucose. Total insulin extracted from the islets in acidified ethanol was carried out as described previously ([@B17]). Insulin was measured by radioimmunoassay (Linco Research, St. Charles, MO).

Luciferase assays.
------------------

Dual-Luciferase Reporter Assay System (Promega) was used according to the manufacturer\'s instructions.

DNA-protein interactions studies.
---------------------------------

HEK293 cells were cotransfected with Myc-tagged ChREBP and HA-tagged MLX for 48 h using calcium phosphate as above before cell lysis and nuclear extracts preparation using NucBuster Protein Extraction Kit (Novagen) according to the manufacturer\'s instructions. DNA-protein interactions were analyzed using the NoShift Transcription Factor Assay Kit (Novagen). Briefly, 5 μg nuclear extracts were incubated with a 3′ biotinylated dsDNA probe and salmon sperm DNA plus Poly(dI-dC) for 30 min on ice before transfer to a streptavidin-coated plate. Mouse monoclonal anti-HA antibody (1/1,000) was added for 1 h at 37°C followed by anti-mouse horseradish peroxidase--conjugated secondary antibody (1/1,000) for 30 min at 37°C. 3,3′,5,5′-Tetramethylbenzidine substrate was added for 30 min to develop colorimetric signal before quenching with 1 N HCl. Absorbance was read at 450 nm.

Statistical analysis.
---------------------

Data are given as means ± SE of three to five individual experiments. Comparisons between means were performed using two-tailed Student\'s *t* test for unpaired data, with Bonferroni\'s correction for multiple tests where appropriate.

RESULTS
=======

ChREBP binds directly and glucose dependently to the ARNT/HIF-1β proximal promoter in living clonal β-cells to regulate its transcription.
------------------------------------------------------------------------------------------------------------------------------------------

To identify genomic targets of ChREBP, we used an unbiased "ChIP-on-chip" approach using high-density oligonucleotide arrays (see [research design and methods]{.smallcaps}). The immediate 5′ flanking region of the ARNT/HIF-1β gene was one of the promoter elements identified on the array as a site at which binding of ChREBP achieved statistical confidence at *P* \< 0.1%. Given previous reports that ARNT/HIF-1β expression in islets is downregulated in type 2 diabetes in humans and that this factor is required for the normal regulation of insulin secretion ([@B8]), we explored the nature and role of the ChREBP-ARNT/HIF-1β promoter interaction in more detail. First, we confirmed, by specific ChIP assay, the binding of ChREBP to a region of the mouse ARNT/HIF-1β promoter that gave the strongest signal on the ChIP-on-chip ([Fig. 1](#F1){ref-type="fig"}*A*, *underlined*), which was located between −249 and −530 bp upstream of the ATG ([Fig. 1](#F1){ref-type="fig"}*B*, *upper panel*). Our anti-ChREBP antibody also immunoprecipitated a region on the mouse [l]{.smallcaps}-PK promoter containing the ChoRE ([@B23],[@B24]) and known to bind ChREBP ([@B13],[@B25]) ([Fig. 1](#F1){ref-type="fig"}*B*, *lower panel*), whereas regions on the ARNT/HIF-1β promoter located either upstream or downstream of −530 to −249 bp area were not pulled down ([Fig. 1](#F1){ref-type="fig"}*B*, *middle panels*). Whereas immunoprecipitation of ChREBP from cells incubated at 3 mmol/l glucose, and PCR amplification of this fragment, generated a relatively minor product, a band of more than threefold greater intensity was generated from cells incubated at elevated glucose concentrations (30 mmol/l; [Fig. 1](#F1){ref-type="fig"}*B*, *upper panel*). These findings thus demonstrated that ChREBP was bound *1*) directly and *2*) in a glucose-regulated manner to the ARNT/HIF-1β promoter in living MIN6 β-cells.

![ChREBP binds to ARNT/HIF-1β promoter in vivo in a glucose-dependent manner. *A*: Sequence of the mouse ARNT/HIF-1β promoter highlighting (bold-italic) those sequences present on the Agilent chip. Underlined is the region that gave the strongest hybridization signal in the ChIP-on-chip assay. The position of the ATG is shown in bold. *B*: MIN6 cells were incubated in 3 versus 30 mmol/l glucose for 16 h, as indicated before cross-linking and chromatin immunoprecipitation using our polyclonal anti-ChREBP antibody. The primer sequences used to amplify mouse ARNT/HIF-1β and [l]{.smallcaps}-PK promoters and the PCR conditions are given in [research design and methods]{.smallcaps}. Data are representative of three independent experiments.](zdb0011059810001){#F1}

To further explore the roles of glucose and ChREBP in controlling ARNT/HIF-1β gene expression, we measured ARNT/HIF-1β mRNA levels in the highly glucose-responsive β-cell line, INS-1 (832/12) ([@B20]). Confirming the glucose sensitivity of ARNT/HIF-1β expression, as recently described ([@B26]), incubation of INS-1 (832/13) cells at 20 versus 3 mmol/l glucose led to a substantial (40--50%) decrease in the corresponding ARNT/HIF-1β mRNA levels ([Fig. 2](#F2){ref-type="fig"}*A*). These findings are consistent with the view that ChREBP induction ([@B27]) and nuclear accumulation ([@B13]) at high glucose concentrations may be involved in the effects of glucose on ARNT/HIF-1β expression. Accordingly, transfection with a siRNA selective for rat ChREBP, which decreased the corresponding mRNA levels by ∼50% ([Fig. 2](#F2){ref-type="fig"}*B*), resulted in a twofold increased in ARNT/HIF-1β mRNA levels at high glucose ([Fig. 2](#F2){ref-type="fig"}*A*). Conversely, adenoviral ChREBP overexpression (supplementary Fig. 1 and [Fig. 2](#F2){ref-type="fig"}*C* in the online appendix, available at <http://diabetes.diabetesjournals.org/cgi/content/full/db08-0868/DC1>) resulted in significant reduction of ARNT/HIF-1β mRNA levels.

![Glucose and ChREBP inhibits ARNT/HIF-1β gene expression in INS-1 (832/13) cells. *A* and *B*: INS-1 (832/13) cells were transfected for 16 h with either ChREBP-specific or -scrambled SiRNAs using TransIT-TKO and Opti-mem or (*C* and *D*) infected with ChREBP expressing or null adenovirus at an multiplicity of infection of 100 and then incubated in 3 mmol/l glucose RPMI for 16 h followed by either 3 or 20 mmol/l glucose RPMI as indicated for 20 h, before total RNA extraction. ARNT/HIF-1β (*A* and *C*) and ChREBP (*B* and *D*) mRNA levels were estimated by quantitative real-time RT-PCR. The results are expressed as mean ± SE of three independent experiments. \**P* \< 0.05 for the effect of glucose.](zdb0011059810002){#F2}

To further analyze the effect of ChREBP binding on ARNT/HIF-1β gene transcription, we next generated promoter-reporter luciferase constructs using fragments of the mouse ARNT/HIF-1β promoter from −2,369 to 293 base pairs with respect to the ATG, a region of the promoter highly conserved between species. Because ChREBP has been shown to regulate lipogenic gene expression as a heterodimer with MLX ([@B28]), we next examined the effects of ChREBP and/or MLX overexpression on ARNT/HIF-1β reporter activity in HEK293 cells. As shown in [Fig. 3](#F3){ref-type="fig"}*A*, overexpression of ChREBP resulted in substantial inhibition of ARNT/HIF-1β promoter activity, even without cotransfection with exogenous MLX, whereas MLX overexpression alone activated the ARNT/HIF-1β promoter. However, as verified by qRT-PCR, MLX was expressed in HEK293 cells \[although at lower levels than in INS-1 (832/13) cells\], whereas ChREBP mRNA was practically undetectable (not shown). To find out whether ChREBP binding to the ARNT/HIF-1β promoter occurs after heterodimerization with MLX in pancreatic β-cells, we performed a ChIP assay in INS-1 (832/13) cells transfected with MLX-HA, using an anti-HA antibody. As shown in [Fig. 3](#F3){ref-type="fig"}*B*, both [l]{.smallcaps}-PK and ARNT/HIF-1β segments of promoter previously pulled down using anti-ChREBP antibody were also immunoprecipitated using anti-HA antibody, whereas the region of ARNT/HIF-1β promoter located between −1,300 and −1,001 bp was not detected. This strongly suggests that ChREBP and MLX form a heterodimeric complex on each promoter.

![ChREBP represses ARNT/HIF-1β promoter activity. *A*: HEK293 cells were seeded in six-well plates and transfected using calcium phosphate with 2 μg pARNT-2369.Luc~FF~, 5 ng pRL-CMV to correct for transfection efficiency, and the indicated amount of plasmid encoding transcription factors ChREBP and/or MLX. Luciferase assays were performed 48 h later as described in [research design and methods]{.smallcaps}. Results are expressed as a percentage of the ratio of Firefly/*Renilla* luciferase in cells with no added transcription factor, as a mean ± SE of four separate experiments. \**P* \< 0.05 and \*\**P* \< 0.005 for the effect of added transcription factor. *B*: INS-1 (832/13) cells seeded in T75 flasks were transfected using lipofectamine 2000 with 8 μg HA-MLX before cross-linking and chromatin immunoprecipitation using either anti-ChREBP or anti-HA antibody as indicated. The primer sequences to amplify the rat [l]{.smallcaps}-PK and ARNT/HIF-1β promoters are given under [research design and methods]{.smallcaps}. Data are representative of three separate experiments.](zdb0011059810003){#F3}

In an attempt to locate the ChREBP/MLX binding site, truncation and deletion mutants were generated in ARNT/HIF-1β luciferase reporter plasmid by restriction digests (see [research design and methods]{.smallcaps} for details) and cotransfected with either empty pcDNA3 vector or pChREBP into HEK293 cells. As expected, and in accordance with the ChIP-on-chip data and the ARNT/HIF-1β--specific ChIP experiment presented in [Fig. 1](#F1){ref-type="fig"}, the deletion mutant lacking the whole proximal region pulled down by ChIP was no longer repressed by exogenous ChREBP ([Fig. 4](#F4){ref-type="fig"}*A*). We next mutated the five consensus individual E-boxes present between −512 and −329 bp on the ARNT/HIF-1β promoter. None of these mutants, at least individually, displayed a loss of ChREBP repression (supplemental Fig. 3*A* in the online appendix). Subsequently, using the NoShift Transcription Factor Assay Kit (Novagen) as an alternative to electrophoretic mobility shift assay, and nuclear extracts from HEK293 cells cotransfected with c-*Myc--*tagged ChREBP and HA-tagged MLX, we scanned the ARNT/HIF-1β promoter between −519 and −220 bp, using overlapping double-stranded DNA probes (supplementary Fig. 2*A*). The [l]{.smallcaps}-PK ChoRE was used as an internal positive control. Because only the probe located between −441 to −411 bp gave a positive signal (supplementary Fig. 2*B*), we generated deletion mutants around this region, but none of these mutants lost ChREBP repression (supplementary Fig. 3*B*), suggesting that ChREBP repression of ARNT/HIF-1β promoter could demand a complex *cis* element configuration.

![ChREBP and glucose repression of ARNT/HIF-1β promoter activity requires cis elements located in the proximal region of the promoter. *A*: HEK293 cells were seeded in six-well plates and transfected using calcium phosphate with 2 μg of the various pARNT.Luc~FF~ constructs, 5 ng pRL-CMV to correct for transfection efficiency, and 250 ng pcDNA3 empty vector or pChREBP as indicated. Luciferase assays were performed 48 h later as in [Fig. 3](#F3){ref-type="fig"}. Results are expressed as a percentage of the ratio of Firefly/*Renilla* luciferase in cells with no added transcription factor, as a mean ± SE of three separate experiments. \**P* \< 0.05 for the effect of ChREBP. *B*: INS-1 (832/13) cells were seeded into 12-well plates and transfected overnight with 450 ng of the various pARNT.Luc~FF~ constructs or pLPK-183.Luc~FF~ as indicated and 1 ng of pRL-CMV as internal control using Lipofectamine 2000 and Opti-mem. The medium was then changed for either 3 or 20 mmol/l glucose RPMI for 20--24 h before cell lysis and luciferase assay. \**P* \< 0.05 for the effect of glucose (*n* = 3--6).](zdb0011059810004){#F4}

Glucose repression of ARNT/HIF-1β gene expression requires the proximal promoter.
---------------------------------------------------------------------------------

To investigate the role of ChREBP in mediating the glucose repression of the ARNT/HIF-1β gene, we transfected the various ARNT promoter-reporter luciferase constructs in INS-1 (832/13) cells and incubated them in 3 or 20 mmol/l glucose for 24 h. Only the construct lacking the whole of the proximal promoter (−1,028 to −769 ARNT) was no longer repressed by glucose; all the other mutants still showed significant glucose repression ([Fig. 4](#F4){ref-type="fig"}*B* and data not shown).

ChREBP overexpression inhibits ARNT/HIF-1β expression and regulates glucose-induced insulin secretion from primary mouse islets.
--------------------------------------------------------------------------------------------------------------------------------

To determine whether the observations reported above in clonal β-cells were relevant to the primary β-cell, we infected isolated mouse islets of Langerhans with ChREBP-overexpressing adenovirus. Whereas endogenous ChREBP mRNA levels were augmented in islets cultured for 20 h at 17 versus 3 mmol/l glucose, as expected, transduction of islets with ChREBP adenovirus caused a \>100-fold increase in ChREBP mRNA levels compared with those observed at either 3 or 17 mmol/l glucose in null adenovirus-transduced islets ([Fig. 5](#F5){ref-type="fig"}*A*). This forced increase in ChREBP expression was associated with a decrease in ARNT/HIF-1β mRNA levels at both low and high (3 and 17 mmol/l) glucose ([Fig. 5](#F5){ref-type="fig"}*B*).

![Overexpression of ChREBP-encoding adenovirus decreases ARNT/HIF-1β gene expression and insulin secretion in primary mouse islets of Langerhans. *A* and *B*: Isolated mouse islets were cultured in 11 mmol/l glucose RPMI and infected with either null or ChREBP adenoviruses at an multiplicity of infection of 100 for 24 h before incubation for 16 h in 3 mmol/l glucose RPMI followed by 20 h in 3 or 17 mmol/l glucose RPMI before total RNA extraction. ARNT/HIF-1β and ChREBP mRNA levels were estimated by quantitative real-time RT-PCR. *C*: Isolated mouse islets were infected as above and maintained in 11 mmol/l RPMI for 48 h before insulin secretion assay. Four groups of six islets per condition were selected and preincubated for 1 h in Krebs-Ringer bicarbonate HEPES buffer containing 3 mmol/l glucose, followed by 30 min at either 3 or 17 mmol/l glucose. Released and total insulin were quantified by radioimmunoassay. The results are expressed as the means ± SE of three independent experiments.](zdb0011059810005){#F5}

We have previously demonstrated that ChREBP silencing enhanced basal and glucose-stimulated insulin secretion from MIN6 β-cells ([@B13]). Correspondingly, we observed here that adenovirus-mediated ChREBP overexpression in mouse islets inhibited GSIS by ∼30% ([Fig. 5](#F5){ref-type="fig"}*C*).

DISCUSSION
==========

The principal aim of the present study was to identify and characterize new target genes that may mediate the effects of ChREBP on β-cell function. To this end, and using an unbiased genome-wide approach, we have identified ARNT/HIF-1β as such a target. Previously shown to be downregulated in type 2 diabetic human islets, and to modulate insulin secretion in the mouse ([@B8]), repression of ARNT/HIF-1β by ChREBP represents an important potential mechanism through which the inhibitory effects of high glucose and of ChREBP may be exerted.

Regulation of ARNT/HIF-1β by ChREBP and glucose.
------------------------------------------------

ARNT/HIF-1β expression has recently been shown ([@B26]) to be elevated at low glucose concentrations in pancreatic MIN6 β-cells. Both ARNT/HIF-1β and presenilin-1 expression were induced by low glucose, the latter being a component of the γ-secretase complex involved in the processing of the β-amyloid precursor processing in the brain, which may regulate β-cell survival via the Notch pathway ([@B26]). It was suggested in these earlier studies that ARNT/HIF-1β lies downstream of presenilin in a signaling pathway activated at low intracellular Ca^2+^ levels. The current data support and extend these findings by demonstrating that ARNT/HIF-1β is regulated by glucose in primary islets as well as in clonal β-cells. Moreover, the present study also supports the view that ChREBP may play a role that is complementary to that of presenilin-1 to control transcription of the ARNT/HIF-1β gene as glucose concentrations change. However, elevated glucose concentrations were still able to decrease ARNT/HIF-1β mRNA levels in the presence of increased, inhibitory, ChREBP levels ([Fig. 3](#F3){ref-type="fig"}), suggesting that multiple signaling mechanisms may be involved in the regulation of ARNT/HIF-1β transcription by glucose. Interestingly, in a previous report ([@B13]), we demonstrated that ChREBP binding to the liver type ([l]{.smallcaps}-) pyruvate kinase gene was regulated in part by an increase in intracellular free Ca^2+^ concentrations. Recent studies by Scott and colleagues ([@B29]) suggested that activation by glucose of the [l]{.smallcaps}-PK gene in INS-1--derived 832/13 cells involves recruitment of *c*-Myc, Max, and ChREBP to the promoter and a glucose-stimulated increase in ChREBP transactivation. Whether the inhibitory effects of ChREBP binding at the ARNT/HIF-1β gene promoter are similarly mediated remains to be explored.

ChREBP has previously been shown to regulate transcription of target genes both positively or negatively, depending on the gene and context ([@B10],[@B12]). Using ChIP, NoShift assay, and mutational analysis, we located the ChREBP/MLX binding site to the proximal region of ARNT/HIF-1β promoter, a region also mediating the negative glucose effect, but the precise *cis* element(s) have remained elusive. Although glucose repression of gene expression in yeast is now well understood ([@B30]), and involves the AMP-activated protein kinase analog Snf1 ([@B31]), our understanding of glucose inhibition of gene expression in mammalian cells is still rudimentary. In primary rat hepatocytes, Ma et al. ([@B28]) found 59 genes that were repressed by high glucose, and only eight of these were also increased by dominant-negative MLX. Whether or not ChREBP was the interacting partner of MLX in regulating the expression of these genes and whether ChREBP/MLX was mediating the glucose response needs further study.

Potential impact of ARNT/HIF-1β regulation on β-cell function.
--------------------------------------------------------------

What may be the physiological consequences for β-cell function or survival of ChREBP-mediated ARNT/HIF-1β repression at high glucose concentrations? The HIF-1 complex is believed to be an important regulator of the response to hypoxic stresses in other cell types ([@B32]). Inhibition of ARNT/HIF-1β expression by high glucose may thus contribute to the deleterious effects on β-cell mass or function during sustained hyperglycemia observed in type 2 diabetes. This may further exacerbate the effects of elevated nuclear levels of ChREBP to drive lipogenic gene expression and hence, potentially, contribute to "gluco-lipotoxicity" ([@B1],[@B33]) under these conditions. Correspondingly, we show here for the first time that ChREBP overexpression inhibits glucose-stimulated insulin secretion from primary mouse islets by ∼50%. Therapeutic approaches that may suppress ChREBP function in islets may thus be useful for the treatment of insulin secretory deficiencies in some forms of type 2 diabetes.
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